Indivior launches authorised generic version of opioid addiction treatment Suboxone as rival generic drugmakers enter market
February 21, 2019Sales and Marketing Alvogen, Dr Reddy's, Novartis, Sandoz, indivior
Indivior has announced the launch of an authorised generic version of Suboxone Film (buprenorphine/naloxone) a combination medicine used to treat …
Pfizer overhauls Xeljanz study over concerns of increased risk of pulmonary embolism and death
February 21, 2019Research and Development Pfizer, Xeljanz, pharma, rheumatoid arthritis
Pfizer is set to overhaul the dosing groups in its ongoing study of Xeljanz (tofacitinib) after an evaluation from a …
Teva settles ‘pay-to-delay’ case with FTC
February 21, 2019Business Services, Sales and Marketing FTC, Teva, antitrust, drugs, generics, monopoly
Teva Pharmaceuticals has settled a dispute with the Federal Trade Commission (FTC) over three separate federal court antitrust lawsuits involving …
Avara Avlon falls into administration putting 270 Bristol jobs at risk
February 21, 2019Manufacturing and Production AstraZeneca, Avara Avlon, Bristol, CDMO, Jobs, UK, manufacturing
Bristol-based pharma firm Avara Avlon Pharmaceuticals has fallen into administration putting the jobs of all 270 of its staff at …
Intercept’s NASH liver fibrosis drug shows promise at Phase 3
February 20, 2019Research and Development Intercept Pharmaceuticals, nash, non-alcoholic steatohepatitis, ocaliva, pharma
Intercept Pharmaceuticals has publicised promising new data on the efficacy of Ocaliva (obeticholic acid) in the treatment of liver fibrosis …
FDA approves Indian firm Alembic’s generic of Teva’s Diamox
February 20, 2019Research and Development ANDA, Alembic, Gujurat, US FDA, diamox, generics
The US FDA has approved Guajarati firm Alembic Pharmaceuticals generic version of Teva’s Acetazolamide sold under the brand name Diamox, …
Pfizer and Eli Lilly’s chronic low back pain (CLBP) treatment meets primary endpoint in Phase 3 trial
February 20, 2019Research and Development
US firms Pfizer and Eli Lilly have said that NGF inhibitor tanezumab met its primary endpoint in a phase 3 …
Poland and Slovenia included in US-EU mutual recognition agreement
February 20, 2019Research and Development EU, GMP, Poland, Slovenia, USA, mutual recognition
Poland and Slovenia have been deemed capable of carrying out Good Manufacturing Practice (GMP) inspections at an equivalent level to …
Keytruda falls short at Phase 3 in advanced liver cancer
February 20, 2019Research and Development Cancer, MSD, keytruda, liver cancer, pharma
MSD has revealed new Phase 3 data which indicates that its blockbuster immunotherapy Keytruda (pembrolizumab), in combination with best supportive …
Philippines’ FDA halts sales of Sanofi’s dengue vaccine
February 19, 2019Manufacturing and Production, Sales and Marketing Philippines, Sanofi, dengue, dengvaxia, pharma
The marketing authorisation for Sanofi’s dengue vaccine Dengvaxia has been revoked in the Philippines after the country’s Food and Drug …
San Francisco scientists use CRISPR to develop stem cells invisible to the immune system
February 19, 2019Manufacturing and Production Nature Biotechnology, Stem cells, UC San Francisco, iPSCs, regenerative medicine
Scientists at UC San Francisco have used the gene editing tool CRISPR Cas9 to manufacture pluripotent stem cells (stem cells …
“Game-changing” osteoarthritis drug receives £675k funding from Innovate UK
February 19, 2019Manufacturing and Production, Research and Development AKL Research and Development, Innovate UK, osteoarthritis, pharma
A novel and potentially “game-changing” oral therapy for the treatment of osteoarthritis (OA) has received a £675,000 cash injection from …
China to establish national rare disease network
February 19, 2019Manufacturing and Production China, NHC, healthcare, rare diseases
China is set to establish a national collaborative network of hospitals for rare disease diagnosis and treatment to promote early …
Japanese researchers to trial stem cell therapy in four patients with serious spinal injuries
February 19, 2019Manufacturing and Production Japan, Keio University, Parkinson's, cell therapy, iPS
The Japanese health ministry has approved a study testing the use of induced pluripotent stem (iPS) cells to treat four …
Beating the flu
February 18, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing flu, influenza, pharma, seqirus
On 14 January, the European Commission issued marketing approval for Flucelvax Tetra, the first cell-based, quadrivalent influenza vaccine. Pharmafocus spoke …
Astellas’ Xtandi “significantly improves” progression-free survival in advanced hormone-sensitive prostate cancer
February 18, 2019Research and Development, Sales and Marketing Astellas, Cancer, Xtandi, pharma, prostate cancer
Japanese pharma firm Astellas has lifted the curtain on new data for its androgen receptor signalling inhibitor Xtandi (enzalutamide), when …
Smoking may limit immune system’s ability to fight cancer, study shows
February 18, 2019Sales and Marketing Cancer, cancer research, immune system, immunology, melanoma, oncology, smoking
Smoking may limit the body’s ability to fight melanoma, according to a study published in the journal Cancer Research. The …
Bavencio+Inlyta combo boosts progression-free survival in advanced kidney cancer
February 18, 2019Research and Development, Sales and Marketing Bavencio, Cancer, Kidney cancer, Merck KGaA, Pfizer, inlyta, pharma
New interim data for the combination of Pfizer’s Bavencio (avelumab) and Merck KGaA’s Inlyta (axitinib) have been released, showing that …
Researchers activate gene to reverse depression in mice
February 18, 2019Sales and Marketing SIRT1, depression, genetics, mental health
Scientists at the Medical College of Georgia at Augusta University were able to directly activate a gene associated with depression …
MSD’s Keytruda combo therapy significantly improves survival in advanced renal cell carcinoma
February 18, 2019Sales and Marketing Cancer, MSD, Merck Sutent, Pfizer, inlyta, keytruda, oncology, rcc, renal cell carcinoma
Merck & Co’s Keytruda (pembrolizumab) in combination with Pfizer’s Inlyta (axitinib) significantly extended the lives of those with advanced renal …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
